Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Income towards Parent Company (2018 - 2025)

TransMedics (TMDX) has 8 years of Income towards Parent Company data on record, last reported at -$68.1 million in Q4 2025.

  • For Q4 2025, Income towards Parent Company fell 139.35% year-over-year to -$68.1 million; the TTM value through Dec 2025 reached $10.5 million, up 7090.41%, while the annual FY2025 figure was $189.2 million, 129456.16% up from the prior year.
  • Income towards Parent Company reached -$68.1 million in Q4 2025 per TMDX's latest filing, down from $19.8 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $33.1 million in Q2 2025 and bottomed at -$68.1 million in Q4 2025.
  • Average Income towards Parent Company over 5 years is -$1.6 million, with a median of -$5.0 million recorded in 2022.
  • Peak YoY movement for Income towards Parent Company: plummeted 239.74% in 2023, then skyrocketed 1318.18% in 2024.
  • A 5-year view of Income towards Parent Company shows it stood at -$12.7 million in 2021, then soared by 334.42% to $29.7 million in 2022, then rose by 4.82% to $31.1 million in 2023, then crashed by 191.39% to -$28.4 million in 2024, then tumbled by 139.35% to -$68.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were -$68.1 million in Q4 2025, $19.8 million in Q3 2025, and $33.1 million in Q2 2025.